Logo

Biocon Biologics’ Yesafili (biosimilar, aflibercept) Receives EC’s Approval for Ophthalmic Conditions

Share this

Biocon Biologics’ Yesafili (biosimilar, aflibercept) Receives EC’s Approval for Ophthalmic Conditions

Shots:

  • The EC has granted marketing authorization for Yesafili, a biosimilar of Aflibercept for the treatment of patients with age-related macular degeneration and diabetic macular edema
  • Yesafili is intended for the treatment of neovascular (wet AMD), visual impairment due to macular oedema secondary to RVO, visual impairment due to DME, and myopic CNV
  • Yesafili was highly similar to the reference aflibercept & the results showed that Yesafili has comparable quality, safety, and efficacy to Eylea. The centralized marketing authorization is valid in all EU Member States, EEA countries Iceland, Liechtenstein, and Norway

Ref: Biocon Biologics  | Image: Biocon Biologics 

Related Post:- Biocon Biologics Receives EMA’s CHMP Positive Opinion of Yesafili (biosimilar, aflibercept)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions